US FDA approves Antisoma's oral fludarabine
This article was originally published in Scrip
Executive Summary
Antisomahas received a boost to its licensing plans for its tablet formulation of its oral fludarabine product, in the form of a US FDA approval for the product as a second-line treatment for chronic lymphocytic leukaemia (CLL).